The trajectory of companies tied to flagship drugs like Viagra presents a challenging investment landscape . While the initial boom of copyright, fueled by Viagra's remarkable popularity, generated substantial wealth , the loss of exclusivity in key territories has introduced significant risk . Investors are now assessing the impact of lower-cost a